阿立哌唑与利培酮治疗精神分裂症的对照研究

目的 比较阿立哌唑与利培酮治疗精神分裂症的疗效.方法 60例符合CCMD-3精神分裂症患者分为两组各30例,分别予阿立哌唑(A组)和利培酮(B组)治疗6周,采用阳性症状与阴性症状量表及不良反应症状量表评定疗效与副反应.结果 两组疗效及不良反应发生率比较差异无显著性意义.结论 阿立哌唑和利培酮对精神分裂症疗效相当,副反应差异亦不显著;但在锥体外系反应,内分泌改变及体重增加方面,阿立哌唑优于利培酮.     

文拉法辛与帕罗西汀治疗抑郁症对照研究

目的 比较文拉法辛与帕罗西汀治疗抑郁症的临床疗效和安全性。方法 对48例抑郁症患者随机分为文拉法辛组与帕罗西汀组，治疗6周。治疗前后用汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）和副反应量表（TESS）评定疗效和不良反应。结果 文拉法辛组有效率87．5％，帕罗西汀组有效率83．3％。两组疗效相仿。但在治疗2周末时，文拉法辛组HAMD减分率下降明显（P〈0．05），两组不良反应均较轻微。结论 文拉法辛和帕罗西汀抗抑郁疗效肯定，不良反应轻。     

阿立哌唑与利培酮治疗慢性精神分裂症的对照研究

目的 探讨阿立哌唑与利培酮治疗慢性精神分裂症的疗效及安全性。方法 对50例慢性精神分裂症患者随机分为2组，分别给予阿立哌唑和利培酮治疗8周，采用阳性与阴性症状量表（PANSS）及副反应量表（TESS）在治疗前后1、2、4、8周末分别评定疗效和副反应。结果 阿立哌唑组和利培酮组疗效间无显著性差异。TESS评定阿立哌唑组副作用小于利培酮组（P〈0．01）。结论 阿立哌唑与利培酮对慢性精神分裂症均有较好的疗效。阿立哌唑具有较小的副作用。     

Association Between Neurotensin Receptor 1 Gene Polymorphisms and Alcohol Dependence in a Male Han Chinese Population

Neurotensin (NT) is a 13-amino acid multifunctional neuropeptide. Previous studies have demonstrated the roles of NT and its high-affinity receptor 1 (NTR1) in genetically mediated differential sensitivities to alcohol. However, no studies have investigated the association between NTR1 gene single-nucleotide polymorphisms (SNPs) and alcohol dependence (AD). We therefore examined this link. We genotyped three SNPs (rs6090453C/G, rs6011914C/G, and rs2427422A/G) of NTR1 gene in 127 AD patients and 131 healthy controls drawn from Han Chinese males. Allele and genotype frequencies were compared, and linkage disequilibrium and haplotype analysis were performed. For rs6011914C/G, the frequencies of GG genotypes in AD patients showed an increased trend compared with controls (p?=?0.057), and the ratio of GG/(CG?+?CC) for dominant model in AD patients was significantly higher (p?=?0.024). For rs2427422A/G, both the frequencies of G alleles and GG genotypes and the ratio of GG/(AG?+?AA) for dominant model in AD patients were significantly higher compared with controls (p?=?0.003, 0.006, 0.002, respectively). There was no significant difference in the frequencies of alleles, genotypes, and dominant or recessive model for rs6090453C/G (all p?>?0.05). There were three pairs of SNP linkage disequilibriums, and the haplotype frequencies differed significantly between patients and controls for the CCA (p?=?0.005, less frequent in the patients) and CCG (p?=?0.002, more frequent in the patients) haplotypes. The current study supported an association between NTR1 gene variants and AD in the Han Chinese population.     

Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized,double-blind,placebo controlled study

Rationale and objective

Depression symptoms are now recognized to be the predominant cause of disability for bipolar disorder (BD) patients. The treatment strategies for the depressed phase of BD remain more anecdotal than data-based. Olanzapine has been investigated as an alternative to antidepressants and a mood stabilizer for acute bipolar depression. The purpose of this study was to assess the efficacy of olanzapine monotherapy for bipolar I depression.

Method

Sixty-eight patients with bipolar I depression were randomly assigned to treatment with olanzapine (mean final dose 14.4 mg/day) (n?=?34) or placebo (n?=?34) in a double-blind parallel-group study design. Planned assessments included Montgomery-Asberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS), Clinical Global Impressions-Severity of Illness scale (CGI-S), Clinical Global Impressions-Improvement scale (CGI-I), Hamilton Depression scale (HAMD), Hamilton Anxiety scale (HAMA), and Treatment Emergent Symptom Scale (TESS).

Results

Of the 68 patients who were randomly assigned, 57 (83.8 %) completed treatments. Improvements in MADRS total score, CGI-S, CGI-I, and HAMD in the olanzapine group were significantly greater relative to those in the placebo group during the 8-week follow-up period (p?<?0.001, p?=?0.0017, p?=?0.007, and p?<?0.001, respectively). Rates of categorical treatment response and remission in the olanzapine group (50.0 % and 35.3 %, respectively) were significantly higher than those in the placebo group (20.6 %, p?=?0.011 and 11.8 %, p?=?0.022, respectively). At the 8-week treatment, the mean weight and the total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels increased significantly in the olanzapine group (p?=?0.037, p?=?0.029, p?=?0.030, and p?=?0.028, respectively).

Conclusions

Olanzapine is effective in the treatment of bipolar I depression but is associated with significant metabolic side effects.     

阿立哌唑维持治疗老年精神分裂症42例临床分析

目的：探讨阿立哌唑对老年精神分裂症患者长期治疗的临床疗效和安全性。方法：采用门诊开放性研究,对42例符合CCMD-3精神分裂症诊断标准的老年患者采用阿立哌唑5-20 mg/日治疗,以简明精神病评定量表（BPRS）评价临床有效性,用药物副反应量表（TESS）评价安全性,观察18个月。结果：有36例完成18个月的疗程,占85.71%（36/42）,BPRS减分率为73.5%,总有效率为83.33%。不良反应有便秘头晕乏力、失眠、静坐不能等,程度多为轻度和中度,未见严重的不良反应。结论：阿立哌唑能有效缓解老年精神分裂症的精神病性症状,安全性好,适合于门诊老年人的长期治疗。     

磁石枕治疗顽固性幻听疗效与脑电地形图变化的关系

目的磁石枕治疗顽固性幻听疗效与脑电地形图变化的关系。方法磁石枕、氯氮平两组患者在入组前及治疗3个月后的脑电地形图检测对比。结果顽固性幻听患者在入组前脑电地形图θ、δ、β频域在各脑区功率值明显增高,而α频域则明显降低,经磁石枕3个月治疗后,各频域、各脑区的功率值趋于正常。氯氮平组治疗3个月后,θ、δ、β各频域、各脑区的功率值变化不明显,可是α频域的功率值则明显增高。结论磁石枕的疗效与脑电地形图的改善有密切关系,α频域的增高与氯氮平的副作用有关。     

面向医疗护理的视觉监控医院患者跌倒检测

提出一种面向医院患者的视觉监控跌倒检测算法,解决患者由于意外跌倒不能被及时发现的问题,为医护人员快速处理患者跌倒等异常行为提供必要的技术保障。方法:首先,基于深度神经网络模型检测监控图像中人体关节点（如肩部、肘部、腕部、胯部、膝关节等）在图像中的位置,再根据亲和度向量场模型提取人体骨架,最后计算患者躯干、腿部与地面的夹角作为判别性特征,判断监控区域内是否有患者出现意外跌倒。结果:实验结果表明,本文所提算法在实际的医院监护环境中的处理速度高达25帧/s,检测准确率高达96%。结论:该方法能够实时、准确地提取医院环境下患者的行为特征,并针对意外跌倒情况发出警报,为医护人员监测患者跌倒等异常行为提供更准确、方便的计算机辅助医疗护理方法。     

基于ID3算法100例中医胃炎实验数据分类挖掘研究

ID3算法是解决数据挖掘分类问题的一个非常重要的方法。本项实验对经过预处理后的100例慢性胃炎的中医辨证数据病例采用ID3算法进行分类,建立中医慢性胃炎辨证分类决策树,并提取决策树中蕴含的知识规则。挖掘出的分类规则基本符合中医胃炎的辨证规律以及名老中医诊治胃炎的诊疗经验。